Oxford Biomedica PLC PDMR Dealing -- Replacement (7386T)

TIDMOXB

RNS Number : 7386T

Oxford Biomedica PLC

16 November 2023

The following amendments have been made to the 'PDMR Dealings' announcement released on 14 November 2023 at 13:43 under RNS No 4264T :

Following this purchase Dr. Michael Hayden holds 39,973 ordinary shares representing 0.0414% of the Company's issued share capital.

All other details remain unchanged.

The full amended text is shown below.

PDMR Dealings

Oxford, UK - 14 November 2023 : Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that Dr. Michael Hayden, a Non-Executive Director of the Company has purchased 10,000 ordinary shares of 50p each ("Ordinary Shares") in the Company on 13 November 2023 on the London Stock Exchange at a price of GBP1.9281. Following this purchase Dr. Michael Hayden holds 39,973 shares representing 0.0414% of the Company.

The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the number of ordinary shares purchased.

 
 1.   Details of the Person Discharging Managerial Responsibility 
       ("PDMR") 
 a)   Name                           Dr. Michael Hayden 
     -----------------------------  ----------------------------------- 
 2.   Reason for the notification 
     ------------------------------------------------------------------ 
 a)   Position/status                Non-Executive Director 
     -----------------------------  ----------------------------------- 
 b)   Initial notification/          Initial Notification 
       amendment 
     -----------------------------  ----------------------------------- 
 3.   Details of the Issuer 
     ------------------------------------------------------------------ 
 a)   Name                           Oxford Biomedica plc 
     -----------------------------  ----------------------------------- 
 b)   LEI code                       213800S1GVQNXQ15K851 
     -----------------------------  ----------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place where 
       transactions have been conducted 
     ------------------------------------------------------------------ 
 a)   Description of                 Ordinary Shares of 50 pence each 
       the financial 
       instrument 
                                      ISIN: GB00BDFBVT43 
       Identification 
       code 
     -----------------------------  ----------------------------------- 
 b)   Nature of the                  P urchase of shares 
       transaction 
     -----------------------------  ----------------------------------- 
 c)   Currency                       GBP - British pound 
     -----------------------------  ----------------------------------- 
 d)   Price(s) and volumes(s)          Price(s)      Volume(s) 
                                        GBP1 .9281    10,000 
                                                     ---------- 
     -----------------------------  ----------------------------------- 
 e)        Aggregated information 
             *    Aggregate volume     10,000 
 
                                       GBP19,281.00 
             *    Aggregated total 
     -----------------------------  ----------------------------------- 
 f)   Date of the transaction        2023-11-13 
     -----------------------------  ----------------------------------- 
 g)   Place of the transaction       London Stock Exchange, Main Market 
                                      (XLON) 
     -----------------------------  ----------------------------------- 
 

-Ends-

 
 For further information, please 
  contact: 
 
   Oxford Biomedica plc:                 Tel: [phone] 
   Natalie Walter, Company Secretary 
 

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com , and follow us on LinkedIn and YouTube .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBUBDBUDBDGXL

(END) Dow Jones Newswires

November 16, 2023 10:32 ET (15:32 GMT)